The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
J Med Microbiol
; 68(6): 898-902, 2019 Jun.
Article
en En
| MEDLINE
| ID: mdl-31050628
The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml-1 for S. aureus (0.12 µg ml-1 against methicillin-sensitive and 0.25 µg ml-1 against methicillin-resistant S. aureus). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml-1 was 2.0 â% (16/790). The clinical outcomes varied by MICs for early clinical response (63-100 â%), end of therapy response (81-100 â%) and the test of cure response (75-100 â%). For microbiological outcomes of these infections, the end of therapy response was 80-100 â% and the test of cure response was 88-100 â%.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pirimidinas
/
Staphylococcus aureus
/
Infecciones Cutáneas Estafilocócicas
/
Antibacterianos
Tipo de estudio:
Clinical_trials
/
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
J Med Microbiol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido